A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 3-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH)
Sponsor: Alnylam Pharmaceuticals
Terminated
Study ALN-HSD-001 was terminated due to business reasons and changes in the development strategy of the product. No safety issues were found.
Other terminated trials from Alnylam Pharmaceuticals
Listed as NCT04565717, this PHASE1 trial focuses on NASH and Nonalcoholic Steatohepatitis and remains terminated or withdrawn. Sponsored by Alnylam Pharmaceuticals, it has been updated 39 times since 2020, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
39 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Terminated PHASE1
-
Apr 2024 — Jun 2024 [monthly]
Terminated PHASE1
Status: Completed → Terminated
▶ Show 34 earlier versions
-
Mar 2024 — Apr 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jan 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE1
-
Dec 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE1
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2023 — Nov 2023 [monthly]
Recruiting PHASE1
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE1
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Apr 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE1
-
Mar 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE1
-
Feb 2023 — Mar 2023 [monthly]
Active Not Recruiting PHASE1
-
Jan 2023 — Feb 2023 [monthly]
Active Not Recruiting PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE1
-
Nov 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE1
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE1
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE1
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE1
-
May 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE1
-
Apr 2022 — May 2022 [monthly]
Active Not Recruiting PHASE1
-
Mar 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE1
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE1
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE1
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE1
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE1
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE1
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE1
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE1
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Alnylam Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .